Key result
Intracoronary nitroprusside improved final TIMI-3 flow and reduced major adverse cardiac events at 6 months compared to nitroglycerin in patients with AMI.
Why the study?
Does intracoronary nitroprusside improve angiographic outcomes and reduce MACE compared to intracoronary nitroglycerin in patients with AMI undergoing primary PCI?
RCT (n=92)
randomly assigned
Does intracoronary nitroprusside improve angiographic outcomes and reduce MACE compared to intracoronary nitroglycerin in patients with AMI undergoing primary PCI?
Intracoronary nitroprusside improves myocardial microcirculation and reduces MACE compared to nitroglycerin in patients with AMI undergoing primary PCI.
Answers are grounded in this paper and cite their sources.
May support preferring intracoronary nitroprusside in AMI primary PCI; extends RCT evidence versus nitroglycerin on flow and MACE.
BACKGROUND: No-reflow phenomenon during percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) is a predictive factor of continuous myocardial ischemia, ventricular remodeling and cardiac dysfunction, which is closely associated with a worse prognosis. This study aimed to evaluate intracoronary nitroprusside in the prevention of the no-reflow phenomenon in AMI. METHODS: Ninety-two consecutive patients with AMI, who underwent primary PCI within 12 hours of onset, were randomly assigned to 2 groups: intracoronary administration of nitroprusside (group A, n = 46), intracoronary administration of nitroglycerin (group B, n = 46). The angiographic results were observed. The real-time myocardial contrast echocardiography (RT-MCE), including contrast score index (CSI), wall motion score index (WMSI), transmural contrast defect length (CDL) and serious WM abnormal length (WML) were recorded at 24 hours and 1 week post-PCI. High sensitivity C-reactive protein (Hs-CRP) was examined by immune rate nephelometry. N-terminal prohormone brain natriuretic peptide (NT-proBNP) was tested with enzyme-linked immunosorbent assay. Patients were followed up for six months. Major adverse cardiac events (MACE) were recorded. RESULTS: The incidence of final TIMI-3 flow in group A was much higher than that in Group B (P < 0.05), final corrected TIMI frame count (cTFC) in group A decreased significantly than that in group B (P < 0.01). The CSI, CDL/LV length, WMSI and WL/LV length in group A were significantly lower than that in group B (P < 0.01). Levels of Hs-CRP and NT-proBNP at 1 week post-PCI decreased significantly in group A than that in group B (P < 0.01). Patients were followed up for 6 months and the incidence of MACE in group A was significantly lower than that in group B (P < 0.05). CONCLUSION: Intracoronary nitroprusside can improve myocardial microcirculation, leading to the decrease of the incidence of no-reflow phenomenon and better prognosis.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2009) conducted an RCT in acute myocardial infarction (n=92). Intracoronary nitroprusside vs. Intracoronary nitroglycerin was evaluated on final TIMI-3 flow (p=<0.05). Intracoronary nitroprusside improved final TIMI-3 flow and reduced major adverse cardiac events at 6 months compared to nitroglycerin in patients with AMI.
Synapse has enriched 10 related papers. Consider them for comparative context: